Editorial
Copyright ©2011 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Jun 21, 2011; 17(23): 2781-2790
Published online Jun 21, 2011. doi: 10.3748/wjg.v17.i23.2781
Targeting key signalling pathways in oesophageal adenocarcinoma: A reality for personalised medicine?
Richard R Keld, Yeng S Ang
Richard R Keld, Yeng S Ang, Department of Gastroenterology, Royal Albert Edward Infirmary, Wigan Lane, Wigan, Greater Manchester, WN1 2NN, United Kingdom
Richard R Keld, Yeng S Ang, School of Translational Medicine, Faculty of Medical and Human Sciences, The University of Manchester, Manchester, M13 9PL, United Kingdom
Author contributions: Keld RR reviewed and searched the literature; Ang YS conceived the idea and revised this paper.
Supported by UK National Institute of Health Research/Cancer Research Network (UK NIHR/UKCRN) and Research and Development Department of Wrightington Wigan and Leigh NHS Foundation Trust (to Ang YS); R Keld Wrightington Wigan and Leigh NHS Foundation Trust Cancer Therapy Fund (to Keld RR, in part)
Correspondence to: Dr. Yeng S Ang, MD, FRCP, FRCPI, FEBG, Consultant Gastroenterologist/Honorary Senior Lecturer, Department of Gastroenterology, Royal Albert Edward Infirmary, Wigan Lane, Wigan, Greater Manchester WN1 2NN, United Kingdom. yeng.ang@wwl.nhs.uk
Telephone: +44-1942-773119 Fax: +44-1942-822340
Received: April 17, 2010
Revised: July 20, 2010
Accepted: July 27, 2010
Published online: June 21, 2011
Core Tip